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Abstract: Cytochrome P450 enzymes (CYPs) are important phase I enzymes involved in the metabolism
of endogenous and xenobiotic compounds mainly through mono-oxygenation reactions into more
polar and easier to excrete species. In addition to their role in detoxification, they play important
roles in the biosynthesis of endogenous compounds and the bioactivation of xenobiotics. Coumarins,
phytochemicals abundant in food and commonly used in fragrances and cosmetics, have been shown
to interact with P450 enzymes as substrates and/or inhibitors. In this review, these interactions and
their significance in pharmacology and toxicology are discussed in detail.
Keywords: cytochrome P450; coumarins; docking; quantitative structure-activity relationship (QSAR);
hologram quantitative structure-activity relationship (HQSAR); comparative molecular field analysis
(CoMFA); comparative molecular similarity index analysis (CoMSIA); molecular modeling; active
site; competitive inhibition; time-dependent inhibition
1. Introduction
1.1. Cytochrome P450s Enzymes
Cytochrome P450 enzymes (CYPs), an important superfamily of Phase I enzymes, are involved
in the metabolism of endogenous and exogenous (xenobiotic) compounds [1–4]. These versatile
enzymes are found in all living organisms and catalyze the mono-oxygenation of a wide variety of
substrates [1]. The primary purpose of P450s is detoxification by oxidizing non-polar molecules into
more polar and excretable ones [5]. Mammalian P450s play important roles in cholesterol and hormone
synthesis, metabolism of endogenous compounds such as vitamin D and bile acids, drug activation and
deactivation, and xenobiotic detoxification [1–4]. About 75% of known enzymatic reactions on drugs are
catalyzed by P450 enzymes [6]. In addition, these enzymes play an important role in carcinogenesis, as
certain pro-carcinogenic compounds are metabolized by P450 enzymes into their ultimate carcinogenic
forms, which are capable of binding DNA and initiating cancer [1,7,8]. P450s are estimated to catalyze
about 66% of bioactivation reactions, many of which lead to cancer formation [9–11].
The Human Genome Project has shown that there are 57 human P450 genes and 58 pseudogenes [1,12].
As more substrates including environmental chemicals and drugs have been discovered for the various
P450 enzymes, their versatility and importance have become more apparent, warranting additional
studies on their mechanisms of action and roles in different diseases including cancer. The development
of selective inhibitors for P450 enzymes involved in carcinogenesis has been the focus of many research
groups, including ours and our collaborators [13–23].
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1.1.1. Basic Enzyme Structure
P450 Enzymes are a superfamily of hemoproteins [1]. Even though the amino acid sequence
identity across the entire P450 superfamily is less than 20%, the enzymes have identical overall fold
structures. The three-dimensional structure of P450s consists of 12 α-helices (A-L), forming the bulk
of the protein, in addition to four β-sheets. The heme is located within the L-helix and the highly
conserved I-helix that is perpendicular to the F/G segment made from the F-helix, F/G-loop and the
G-helix [23]. The heme-Fe atom is bound to the sulfur atom of the cysteine amino acid in the adjacent
loop, which contains the highly conserved sequence FxxGx(HRK)xCxG [23]. Substrate access and
specificity for the various P450 active sites are determined by the B-C and F-G helices [23]. Crystal
structures of many P450 enzymes have already been published [24–31].
1.1.2. Catalytic Activity Cycle
The catalytic activity starts once a substrate is bound to the enzyme, and the low-spin ferric
heme-iron (coordinated to a water molecule as its sixth ligand in its resting state) changes to a high-spin
ferric state in the enzyme-substrate complex. The heme-iron then binds an oxygen molecule to form a
stable oxy-iron-enzyme complex. This oxy-iron-enzyme complex is then reduced to form an unstable
peroxo-ferric-enzyme complex, followed by the protonation of the distal oxygen to form an unstable
hydroperoxo-iron-enzyme complex. A second protonation of the same oxygen is then followed by
heterolytic cleavage of the bond between the two oxygen atoms leading to the formation of a reactive
high-valent iron-oxo-enzyme complex and water. This complex then abstracts a hydrogen atom
from the substrate with subsequent radical recombination to form the product (oxidized form of the
substrate). After the release of the product, water binds to the heme-iron, regenerating the resting P450
enzyme (Figure 1) [1,23].
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Figure 1. The catalytic oxidation cycle of cyt chrome P450 enzymes—Th heme-Fe atom is covalently
bound to the sulfur atom of a cysteine amino acid residue in the enzyme active site [23].
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1.2. Coumarins
Coumarins are natural products found in plants, fungi, and bacteria [32]. They are commonly
found in food and also widely used in cosmetics and fragrances [33,34]. Coumarins show a variety of
biological activities, including anti-oxidant, anti-cancer, anti-coagulant, anti-inflammatory, anti-fungal,
anti-microbial, anti-viral, anti-neurodegenerative, and anti-diabetic activities [32–34]. Coumarin
(2H-1-benzopyran-2-one) backbone structure is made of fused benzene and α-pyrone rings [35,36].
This conjugated structure also leads to coumarins’ applications as fluorescent sensors for biological
activities [32]. There are six types of coumarins based on their extended backbone structures: 1) Simple
coumarins; 2) Dihydrofuranocoumarins; 3) Furanocoumarins (linear and angular); 4) Pyranocoumarins
(linear and angular); 5) Phenylcoumarins; and 6) Bicoumarins (Figure 2) [36].
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1.2.1. Coumarins and P450s
Due to the importance of understanding the interactions between coumarins and cytochrome
P450 enzymes and their biological effects, especially on human health, this review is focused on studies
of such interactions and lessons learned.
The P450 enzymes have a wide range of natural product substrates and inhibitors including
coumarins [37–41]. For example, citrus fruits are rich in coumarins such as bergamottin, a linear
furanocoumarin found in grapefruits, that potently inhibits several P450 enzymes including P450s 1A1,
1A2, 2A6, 2B6, 2D6, 3A4, and 3A5 [42,43]. These interactions are especially important in pharmacology
as many of these P450s are required for bioactivation and/or metabolism of drugs in vivo, and
their inhibition can lead to lower bioavailability of the drugs’ active metabolites and/or higher
concentrations of the drugs in the blood or tissues that are prone to drug toxicity. Furanocoumarins
are secondary metabolites in citrus plants and protect the plants against other organisms including
insects [41]. Interestingly their biosynthesis in plants is also heavily P450 dependent [44]. A new
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X-ray crystal structure of P450 1A1 with bergamottin in its active site has been published recently,
showing that the P450 1A1 active site is malleable and opens up as needed to accommodate large
substrates [28]. This specific P450 enzyme is heavily involved in human carcinogenesis, thus its
inhibition has been studied for cancer chemoprevention [28]. Bergamottin has been shown to have
chemo-preventive effects in mice, inhibiting benzo[a]pyrene metabolism by P450 1A1 to its carcinogenic
form, anti-benzo[a]pyrene-7,8-diol-9,10-epoxide, and the resulting production of DNA adducts and
cancer formation [45]. Another naturally occurring linear furanocoumarin, methoxsalen, is a very
potent mechanism-based, non-selective inhibitor of human P450s, and is used as a drug for the
treatment of a number of skin diseases such as psoriasis [46,47]. Two other linear furanocoumarins,
imperatorin and isopimpinellin, have been shown to have anti-cancer activities in a murine breast
cancer model through the inhibition of P450 1A1/1B1 metabolism of 7,12-dimethylbenz[a]anthracene
(DMBA) and blocking DMBA-DNA adduct formation [48].
Figure 3 contains the structures of a number of natural coumarin P450 substrates and inhibitors [45].
Coumarins exhibit significant species differences in metabolism and toxicity [37,40].
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1.2.2. Coumarin Metabolism by P450s
As mentioned previously, P450 metabolism of coumarins is species dependent. Coumarin has
been found to be a rat liver and mouse lung toxicant due to the P450-dependant production of
coumarin-3,4-epoxide by P450s 1A1, 1A2, and 2E1 in liver and P450 2F2 in lung (Figure 4) [37,49].
3-Hydroxycoumarin has been found as a minor metabolite of coumarin metabolism by recombinant
rat P450s 1A1 and 1A2 [37].
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In humans, only about a dozen of the 57 CYP genes, those belonging to CYP families 1, 2, and
3, are involved in the metabolism of xenobiotics including about 80% of current clinical drugs [50].
Expression of these genes to corresponding enzymes (P450s 1A1, 1A2, 1B1, 2A6, 2A13, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1, 2J2, 3A4, and 3A5) is influenced by combinations of different factors including genetic
polymorphisms, sex, age, ethnicity, general health conditions, and induction by xenobiotics [50].
The human P450 1 family has three enzymes from two subfamilies, P450s 1A1 and 1A2 from
subfamily 1A and P450 1B1 from subfamily 1B. P450s 1A1 and 1B1 are primarily extrahepatic enzymes
while P450 1A2 is mainly found in the liver. With 72% amino acid sequence similarity, the enzymatic
activities of P450s 1A1 and 1A2 greatly overlap and mainly include the hydroxylation and oxidation of
aromatic compounds including polycyclic aromatic hydrocarbons (PAHs). Coumarin is metabolized
by these human enzymes into comarin-3,4-epoxide at a much lower rate than observed in rodents,
and thus does not cause the same high toxicity [49]. P450 1B1 has relatively low amino acid sequence
similarity with both P450 1A1 and P450 1A2, 38% and 37% respectively, however, it in general has a
similar active site cavity shape and size (441 Å3 for 1B1, 469 Å3 for 1A2, and 524 Å3 for 1A1) leading
to significant substrate specificity overlap with these enzymes (such as PAHs, heterocycle aromatic
amines, and estradiol) [24]. P450s 1A1, 1A2, and 1B1 do not show much coumarin 7-hydroxylase
activity. P450 1B1 also does not show coumarin 3,4-epoxidase activity. 3-Hydoxycoumarin has been
shown to form as a minor metabolite during the incubation of coumarin with recombinant human
P450 1A1 or P450 1A2 [37]. All three enzymes show 7-alkoxycoumarin dealkylation activities [48]. The
order of rates of 7-ethoxy-4-trifluoromethylcoumarin deethylation by these three enzymes has been
shown to be P450 1A1 > P450 1B1 > P450 1A2 [51].
There are 16 CYP2 genes in humans, and most show high levels of genetic polymorphisms [50].
From the CYP2A subfamily, only CYPs 2A6 and 2A13 are functional and both show significant
genetic polymorphisms. P450 2A6 is mainly hepatic, while P450 2A13 is mainly expressed in the
respiratory tract. Most substrates for these enzymes, which have 94% amino acid sequence similarity,
are non-planar, low molecular weight compounds which contain two hydrogen bond acceptors [50].
The two only differ in 32 amino acids, ten of which are located in their relatively small active sites
(<300 Å3) [8,24]. P450 2A6 is responsible for the metabolism of about 3% of clinically used drugs
(such as disulfiram, halothane, and tegafur) in addition to the metabolism and bioactivation of tobacco
nitrosamines (nicotine and NNK (4-methylnitrosamino-1-3-pyridyl-1-butanone)) [50]. Polymorphisms
in P450 2A6 are responsible for individual differences in the rate of nicotine metabolism, smoking
behavior, and cancer risk associated with tobacco use [50]. P450 2A13 is similar in substrate specificity in
general. However, it is much more efficient in the bioactivation of NNK [50]. Both enzymes are known
to catalyze coumarin 7-hydroxylation and 7-alkoxycoumarin dealkylation [29,50]. The deethylation of
7-ethoxycoumarin and the demethylation of 7-methoxycomarin have been shown to produce both
7-hydroxycoumarin and 3-hydroxycoumarin as products, though the 3-hydroxylation was observed at a
greater extent during the deethylation reaction [29,52]. Since position 7 has been shown to be the closest
to the heme-iron, the production of the 3-hydroxy product implies rotation of the substrate during the
reaction to produce this product [53,54]. P450 2A6 is the major coumarin 7-hydroxylase in the human
liver, and the X-ray crystal structure of the enzyme-substrate complex has been published showing a
tight fit of the coumarin molecule in the small P450 2A6 active site (260 Å3) [29,30]. Neither 2A6, nor
2A13, produce 3-hydroxycoumarin during oxidation of coumarin [29]. From the CYP2B subfamily,
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only CYP2B6 is functional in humans [55]. P450 2B6 has been shown to efficiently O-deethylate
7-ethoxy-4-trifluoromethylcomarin [50]. Mammalian P450s 2B35 and 2B37 from the desert woodrat
(Neotoma lepida) have been studied for O-dealkylation activities with series of 7-alkoxycoumarins,
7-alkoxy-4-trifluoromethylcoumarins, and 7-alkoxy-4-methylcoumarins with a C1-C7 side chain, and
have been shown to display differences in their substrate selectivity based on the length of the O-alkyl
group [31]. P450 2B35 shows higher activity in O-dealkylation of long-chain coumarin derivatives
(7 and 6 carbon chains), while P450 2B37 shows preference for short-chain coumarin derivatives
(such as 7-ethoxy-4-trifluoromethylcoumarin) [31]. The crystal structures of these two enzymes in
complex with 4-(4-chlorophenyl)imidazole (4-CPI) have confirmed that P450 2B35 fits two 4-CPI
molecules in its active site, while P450 2B37 only fits one in the active site, though it has an open
conformation with two more 4-CPI molecules in its substrate access channel [31]. Rabbit P450 2B4
has a 78% amino acid sequence similarity with human P450 2B6. Crystal structures of P450s 2B4 and
2B6 have been shown to only contain one 4-CPI molecule in their active sites [56,57]. P450s 2B4 and
2B6 also show coumarin substrate selectivity based on the side chain length at position 7, as well
as substitution at position 4 [55]. These observations confirm that P450 2B family enzymes show
significant differences within their flexible active sites and substrate access channels across various
species, and bind a wide range of ligand sizes and shapes [31]. The CYP2C subfamily members in
humans are CYPs 2C8, 2C9, 2C18, and 2C19; though 2C18 mRNA is not efficiently translated to protein,
and thus this enzyme is not expressed in high concentrations [50]. Polymorphisms in these genes
significantly affect drug metabolism. P450 2C9 is the main enzyme from this subfamily involved in the
metabolism of coumarins, and polymorphisms have been shown to lead to coumarin sensitivity and
toxicity, especially for patients on coumarin anti-coagulants (such as warfarin, acenocoumarol, and
phenprocoumon) [58]. Warfarin is used as a racemic mixture of R and S enantiomers, however, the S
enantiomer is 2–5 times more potent. Both enantiomers are hydroxylated by P450 enzymes during
metabolism leading to their excretion in urine (Figure 5). S-warfarin is mainly metabolized by P450 2C9
to the 6-, and 7-hydroxy metabolites which are easily excreted and limit the drug’s toxicity. R-warfarin
is metabolized by P450s 1A1, 1A2, and 3A4, so one enzyme containing a polymorphism does not have
as much effect [59]. CYP2D6 is the only active gene from this subfamily in humans [50]. P450 2D6
is non-inducible, however, its hepatic concentration varies significantly between individuals due to
polymorphisms [60]. This enzyme is involved in the metabolism of 15–25% of clinically used drugs,
thus its genetic polymorphisms play important roles in the upregulation or downregulation of their
pharmacological and toxicological effects [50]. P450 2D6 has been shown to perform 7-dealkylation
reactions on 7-alkoxycoumarins such as 7-methoxy-4-aminomethylcoumarin [61]. Human P450 2E1
is an inducible enzyme and mainly metabolizes small polar molecules such as ethanol but also has
some larger aromatic substrates including coumarins. P450 2E1 metabolism of ethanol leads to the
formation of reactive oxygen species leading to liver cell damage in heavy drinkers [50]. Metabolism
of coumarins by this enzyme leads to epoxidation at the 3,4 positions, dealkylation at the 7 position,
and/or hydroxylation at different positions as previously discussed [37,49,62]. In addition, human
P450 2F1 also efficiently catalyzes 7-ethoxycoumarin O-deethylation [63].
From the P450 family 3, the main human genes are CYP3A4, CYP3A5, CYP3A7, and CYP3A43.
However, only P450s 3A4 and 3A5 are important in the metabolism of xenobiotics and clinical drugs,
both of which show high levels of polymorphism. Tacrolimus, an immunosuppressant drug used
in transplant patients, is metabolized by P450 3A5; thus, P450 3A5 genetic polymorphism testing is
important to determine the correct dosage based on the patients’ rate of drug metabolism. P450s
3A4 and 3A5 have large active sites (~1400 Å3), over 85% amino acid sequence similarity, and are
known to metabolize large lipophilic molecules [50]. These enzymes debenzylate 7-benzyloxy-4-
trifluoromethylcoumarin, and their activities can be inhibited by some natural coumarins such as
bergamottin leading to drug interactions [45–48,50,64].
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ecent explorations of controlled drug delivery have pointed to engineering of photo-responsive
nanoparticles as site targeted drug delivery systems [65–67]. These engineered nanoparticles should
have the ability to hold on to the biologically active molecule (drug) until they reach the targeted
site, where upon the irradiation of the photo-responsive group (“photo-cage” or “caging group”)
the molecule in its active state could be released [68,69]. Due to their water solubility, versatility of
their incorporation into varied types of nanoparticles, and their absorption in the visible part of the
spectrum, coumarins have elicited extreme interest in this area. The photo-responsive properties of
coumarins have made them the photo-cage olecule of choice for the recent studies on drug delivery.
One of the main limitations of such strategy is the toxicity/drug interactions of the coumarins an the
products of metabolism of the released coumarins by cytochrome P450 enzymes. Figure 6 shows the
coumarin structures that have shown promise in photo-caging [68,70].
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1.2.3. P450 Inhibition Mechanism by Coumarins
P450 inhibition follows two distinct mecha isms, direct competitive inhibition and time-dependent
inhibition. Direct competitive inhibitors are substrate-like molecules capable of entering and temporarily
binding to the enzyme active site while being metabolized; once the metabolites are released, the enzyme
returns back to its free state. For these compounds to be effective inhibitors, they have to show higher
affinity toward the enzyme than its natural substrates, thus keeping the enzyme busy and reducing
its substrate turn-around rate. Time-dependent inhibitors, also often resemble natural substrates in
structure, giving them access to the enzyme active site; in addition, enzyme incubation in their presence
leads to increased inhibition. Mechanism-based (suicide) inhibitors are time-dependent inhibitors that
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are metabolized by the enzyme to reactive intermediates which covalently bond the active site residues
and permanently inhibit the enzyme’s activity [71–73]. This process is both time- and cofactor-dependent.
Coumarins can act as substrates, direct competitive inhibitors, or time-dependent inhibitors.
Our group and collaborators have focused on the development of selective mechanism-based
inhibitors for certain P450 enzymes involved in carcinogenesis including a number of coumarin
derivatives [13–23,38,74]. P450s 1A1, 1A2, 1B1, 2A6, 2E1, and 3A4 are responsible for about 77% of
all bioactivation reactions catalyzed by P450s, thus their inhibition has been studied as a potential
means of cancer prevention [1,13,16,18,20,21,24,25,74,75]. However, P450 inhibitors have the potential
for inducing the over-expression of P450 enzymes by activating the aryl hydrocarbon receptor (AhR)
limiting their use as clinical cancer preventive agents. An ideal P450 inhibitor for use in cancer
prevention should not cause AhR activation. Mechanism-based inhibitors could also be used as probes
of the enzyme active site structure and reaction mechanisms [1].
P450 3A4 is involved in the bioactivation of environmental procarcinogens such as aflatoxin B1, aflatoxin
G1, and dihydrodiol derivatives of PAHs [76]. 7-Coumarin propargyl ether and 7-(4-trifluoromethyl)
coumarin propargyl ether (structures shown in Figure 7) were designed and synthesized by
our group, combining the structural features of a known substrate for P450s 3A4 and 3A5,
7-benzyloxy-4-trifluoromethylcoumarin (BFC), with the propargyl functional group previously shown
to have a potential inhibitory effect on P450s [38]. When correctly oriented, the terminal triple bond is
oxidized by the enzyme into a reactive ketene intermediate through a 1,2-hydrogen shift, leading to
the formation of a covalent bond with a nucleophilic amino acid residue in the active site and loss of
enzymatic activity [1,20]. Both compounds in this study inhibited the BFC O-debenzylation activity of
P450 3A4 in a mechanism-based manner (time-, concentration-, and NADPH-dependent) [34]. Neither
compound showed mechanism-based inhibition of BFC O-debenzylation by P450 3A5, showing
selectivity for P450 3A4 [38]. This observed variation in the catalytic activity of the two enzymes with
these coumarin derivatives has been attributed to their difference in 78 amino acids (out of the total
503 in their sequences), of which 17 are located in their substrate recognition sites (SRSs) leading to
different ligand-enzyme interactions [38].
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As previously discussed, P450s 1A1 and 1A2 are involved in the bioactivation of many
environmental chemicals such as PAHs [1,74,75]. P450 1A1 prefers larger planar molecules such
as benzo[a]pyrene and DMBA, while P450 1A2 prefers smaller planar triangle-shaped molecules
including aryl and heterocyclic amines [74,75]. A series of 7-ethynylcoumarin derivatives were
designed, synthesized, and evaluated by us for potential inhibitory effects and selectivity toward
P450s 1A1, 1A2, 2A6, and 2B1 [22]. These compounds were also designed by combining the coumarin
backbone, a known P450 substrate, with the ethynyl functional group previously shown to cause
mechanism-based inhibition [1,38]. All of the compounds in this study, except 7-ethynyl-3-methyl-4-
phenylcoumarin (7E3M4PC) showed mechanism-based inhibition of P450s 1A1 and 1A2, and no
inhibition of P450s 2A6 and 2B1 [22]. The most potent and selective compound in the study was
7-ethynyl-3,4,8-trimethylcoumarin (structure shown in Figure 8) [22]. Methoxsalen has been shown to
inhibit P450 2A6 but lacks selectivity as it also inhibits other P450 enzymes such as P450s 3A4 and 2D6.
Molecules 2019, 24, 1620 9 of 17
5-Methoxycoumarin and 6-methoxycoumarin have been shown to inhibit P450 2A6 selectively (IC50
values of 0.13 and 0.64 mM, respectively) [77].Molecules 2019, 24, x FOR PEER REVIEW 9 of 17 
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In a more recent study, our group designed and studied a number of furano-, pyrano-, pyridino-and
dioxolo-coumarin derivatives as potential inhibitors for P450 1A2 [63]. One of the compounds in this
study, 4-trifluoromethyl-7,8-pyranocoumarin, was found to be a competitive inhibitor, showing high
selectivity for the inhibition of this enzyme, with selectivity indices of 155 and 52 for P450 1A2 over
P450s 1A1 and 1B1, respectively (structure shown in Figure 9) [63]. This selectivity is of importance
since most known P450 1A2 inhibitors also inhibit P450s 1A1 and 1B1 (80% and 40% amino acid
sequence similarity, respectively). In yeast AhR activation assays, at concentrations lower than 1 µM,
this pyranocoumarin did not activate the receptor suggesting that it would not up-regulate AhR-caused
P450 enzyme expression [63]. These results show that 4-trifluoromethyl-7,8-pyranocoumarin is selective
for the inhibition of P450 1A2 and has the potential for use in cancer-prevention [63].
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1.2.4. Computational Molecular Modeling Studies
Cou arin metabolism studies have shown that sites of oxidation are species dependent and
human P450 enzyme oxidation of coumarins mainly produces 7-hydroxycoumarin, with four other
products formed only in minor amounts due to 3,4-epoxidation, and hydroxylation at the 3-, 6-, or
8- positions (Figure 10) [78–87]. Kinetic studies have been used to show that P450s 1A1, 1A2, 2B6
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and 2E1 catalyze metabolism of coumarin to its 3,4-epoxide which then leads to the formation of the
ortho-hydroxyphenylacetaldehyde as the metabolite [37,82]. P450 2A6 oxidizes coumarin at the 7-position
leading to the formation of the 7-hydroxycoumarin metabolite [37,82]. P450 3A4 metabolism leads to
the formation of two metabolites, namely, 3-hydroxycoumarin and ortho-hydroxyphenylacetaldehyde,
through the coumarin 3,4-epoxidation pathway [82]. Computational molecular modeling tools have
been used by several research groups to understand the interactions of coumarin molecules with
the P450 enzymes. Studies have included docking studies of coumarins in the active sites of the
P450 enzymes. Quantitative structure-activity relationship (QSAR) studies have provided important
information on structural features of coumarins as P450 substrates [19,22,39,61,83,84]. The binding
modes of coumarins vary depending on the nature and position of substituents and the P450 enzyme
binding cavity topography [13,23]. Docking studies have been performed by Lewis et al. in order to
understand the role of P450 binding cavity residues in the oxidative pathways of coumarin [39]. One
of the key interactions shown by coumarins is the π-π stacking interactions with the phenylalanine
residues in the binding pocket [39,84]. Additionally, interactions with a hydrogen-bonding residue
determine the binding orientation of coumarin in the binding pocket and its site of oxidation [39,84]. The
differences in spatial arrangements of the hydrogen-bonding residues and the phenylalanine residues
have been shown to result in differences in the binding mode and product formation. For example,
in P450 2A6, the Asn290 forms a hydrogen bond with the coumarin carbonyl group, resulting in the
orientation of the 7-position towards the heme-Fe, resulting in the formation of 7-hydroxycoumarin [39].
In P450 3A4, the hydrogen bonding of the coumarin carbonyl with a Ser119 in the binding pocket leads
to the 3-position facing the heme-Fe, and the formation of the 3-hydroxycoumarin [39].
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Coumarin is the marker substrate for the cytochrome P450 2A family, consisting of P450s 2A6 and
2A13. As previously mentioned, these enzymes have 94% amino acid sequence identity. The catalytic
efficiency of coumarin 7-hydroxylation was found to be higher for P450 2A6 than P450 2A13 (10 fold) by
He et al. [85], while Weymarn and Murphy found that both enzymes had similar efficiency [86]. DeVore
et al. measured spectral binding affinities (KD) for coumarin and found equal binding affinities to both
P450s 2A6 and 2A13 [87]. The planar active site and Asn297 are conserved in both enzymes. DeVore
et al. performed receptor-based QSAR studies using the comparative binding energy (COMBINE)
approach and identified individual protein/ligand interactions. These studies revealed that the binding
orientation was similar for both proteins with coumarin forming a hydrogen bond to Asn297. This
was consistent with both enzymes generating 7-hydroxycoumarin with identical KD values. While
P450 2A6 exclusively formed 7-hydroxycoumarin, von Weymarn and Murphy [86] found that P450
2A13 formed significant amounts of 3,4-epoxide and smaller amounts of 6-hydroxycoumarin and
8-hydroxycoumarin in addition to 7-hydroxycoumarin. DeVore et al. found that the approach path
of coumarin substrate to the activated oxygen on the heme was less constrained in P450 2A13 than
in P450 2A6, leading to hydroxylation at the 6- or 8- positions, and also the inverted orientation of
coumarin that resulted in 3,4-eopxide [87]. Comparison of the active site residues between P450s 2A6
and 2A13 revealed that 10 out of 32 residues differ between the two enzymes, potentially correlating to
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the functional differences in substrate metabolism. The COMBINE QSAR model generated by DeVore
et al. suggested that steric roles played by the active site residues were primarily responsible for the
differing ligand affinities [87].
Homology models of rat and human P450 2D isozymes (2D1, 2D2, 2D3, 2D4, and 2D6) have
been built and studied [61]. Docking followed by molecular dynamic simulations were carried on
7-methoxy-4-aminomethylcoumarin [61]. The models showed that the Asp301 residue of these enzymes
form hydrogen bonds with the basic nitrogen of 7-methoxy-4-aminomethylcoumarin, resulting in its
O-demethylation [61].
Docking studies were performed in our laboratory for a series of ethynylcoumarins with P450
enzymes 1A1 and 1A2 using the LigandFit in the Accelrys DS studio® (Figure 11) [22]. These studies
showed that π-π interactions of the coumarins with the phenylalanine residues of the active site are
critical determinants of the binding mode of the inhibitors. Changes in orientations guided by the
position of the phenyl substituents dictate the nature of inhibition as a competitive or time-dependent
inhibitor of the P450 1A2 enzyme. In the absence of a phenyl substituent, the ethynyl groups were
the closest to the heme-Fe, enabling the generation of a highly reactive oxidation intermediate that
could then react with the receptor residues to form covalent interactions leading to a time-dependent
inhibition and inactivation of the enzyme. The presence of a 3-phenyl substituent on the coumarin
ring flipped the molecule’s orientation in the active site to facilitate the phenyl group’s facing the
heme-Fe, and the ethynyl group facing away from the heme. This leads to these molecules acting
as competitive inhibitors of P450 1A2. P450 1A1 has a larger active site cavity in comparison to
P450 1A2. This results in multiple binding modes for the ethynyl coumarin series studied leading to
some of the binding modes orienting the ethynyl group in close proximity to the heme-Fe causing
time-dependent inhibition by all of these compounds. QSAR studies were performed on a series
of 7-coumarin propargyl ethers using comparative molecular field analysis (CoMFA), comparative
molecular similarity index analysis (CoMSIA) and hologram quantitative structure-activity relationship
(HQSAR) modules in Tripos-Sybyl [19]. These analyses showed that there are equal contributions
from steric, electrostatic and ClogP descriptors towards the inhibition potency of these compounds
toward P450 1A2, indicating that lipophilicity is an important factor. The contour maps of steric and
electrostatic plots were generated for the binding pocket of P450 1A2 [19]. Lewis et al. performed
QSAR analysis on a series of 7-alkoxycoumarins that are used as diagnostic probes for the P450 2B
enzymes [84]. The logP data which is a lipophilicity index was obtained experimentally and by
calculations via the ClogP. They found a quadratic relationship between the logP of 7-alkoxycoumarins
and the experimentally determined logarithm of the dealkylation activity in phenobarbital-induced
animals. Hydrophobicity was found to be a key factor in the P450 2B and substrate interactions.
Additional interactions such a hydrogen bonding and pi-pi interactions were also found to be relevant.
Leong et al. used a hierarchical support vector regression (HVSR) approach to predict the interactions
of several drugs with P450 2B6 [88]. Cytochrome P450 2B6 is a hepatic enzyme constituting 1% of
the total hepatic P450 complement [89], but metabolizes 3% of the clinical drugs [90]. Five coumarins,
7-ethoxycoumarin, 7-ethoxy-4-trifluoromethylcoumarin, 7-methoxy-4-trifluoromethylcoumarin, 3-cyano
-7-ethoxycoumarin, and 4-chloromethyl-7-ethoxycoumarin were used in this study [88]. The generated
HVSR model showed a relation between the experimental and predicted values, which were statistically
true (correlation coefficient q2 of 0.93 and r2 values of 0.97 and 0.82 for the training set and test set,
respectively for the 10-cross validation of the model) [88]. Out of a total of 10 descriptors, logP’s were
shown to be of critical importance, and the descriptors relating to the molecular size and shape were also
important contributors to the model [88].
The docking and QSAR studies by various research groups have provided a deeper understanding
of the nature and types of interactions of coumarins with the active site residues of P450 1A, 1B, 2B, 2C,
2D and 3A enzymes.
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